Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy Vaxart stock
Own Vaxart stock in just a few minutes.
Vaxart, Inc is a biotechnology business based in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Vaxart employs 16 staff and has a trailing 12-month revenue of around USD$7.8 million.
How to buy shares in Vaxart
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Vaxart Find the stock by name or ticker symbol: VXRT. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vaxart reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Vaxart, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Vaxart. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Vaxart share price
Use our graph to track the performance of VXRT stocks over time.Vaxart shares at a glance
Information last updated 2020-09-25.
| 52-week range | USD$0.266 - USD$17.49 |
|---|---|
| 50-day moving average | USD$7.5557 |
| 200-day moving average | USD$5.3783 |
| Wall St. target price | USD$19.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.033 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Vaxart stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Vaxart price performance over time
Historical closes compared with the last close of $N/A
| 1 week (2020-09-17) | -100.00% |
|---|---|
| 1 month (2020-08-27) | -100.00% |
| 3 months (2020-06-26) | -100.00% |
| 6 months (2020-03-27) | -100.00% |
| 1 year (2019-09-27) | -100.00% |
|---|---|
| 2 years (2018-09-27) | -100.00% |
| 3 years (2017-09-27) | -100.00% |
| 5 years (2015-09-25) | -100.00% |
Vaxart financials
| Revenue TTM | USD$7.8 million |
|---|---|
| Gross profit TTM | USD$-4,678,000 |
| Return on assets TTM | -17.91% |
| Return on equity TTM | -78.26% |
| Profit margin | -281.5% |
| Book value | $0.419 |
| Market capitalisation | USD$752.4 million |
TTM: trailing 12 months
Shorting Vaxart shares
There are currently 13.4 million Vaxart shares held short by investors – that's known as Vaxart's "short interest". This figure is 2.9% down from 13.8 million last month.
There are a few different ways that this level of interest in shorting Vaxart shares can be evaluated.
Vaxart's "short interest ratio" (SIR)
Vaxart's "short interest ratio" (SIR) is the quantity of Vaxart shares currently shorted divided by the average quantity of Vaxart shares traded daily (recently around 14.4 million). Vaxart's SIR currently stands at 0.93. In other words for every 100,000 Vaxart shares traded daily on the market, roughly 930 shares are currently held short.
However Vaxart's short interest can also be evaluated against the total number of Vaxart shares, or, against the total number of tradable Vaxart shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaxart's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Vaxart shares in existence, roughly 120 shares are currently held short) or 0.1613% of the tradable shares (for every 100,000 tradable Vaxart shares, roughly 161 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaxart.
Find out more about how you can short Vaxart stock.
Vaxart share dividends
We're not expecting Vaxart to pay a dividend over the next 12 months.
Have Vaxart's shares ever split?
Vaxart's shares were split on a 1:11 basis on 14 February 2018. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.
Vaxart share price volatility
Over the last 12 months, Vaxart's shares have ranged in value from as little as $0.266 up to $17.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is -0.0427. This would suggest that Vaxart's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vaxart has bucked the trend.
Vaxart overview
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Frequently asked questions
Ask an Expert